Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Martin Hutchings

Martin Hutchings

Copenhagen University Hospital
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL 2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
Martin Hutchings • 10 Dec 2023
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS 3:58
Extended follow-up of glofitamab monotherapy in R/R LBCL: durability of CR and likelihood of CRS
Martin Hutchings • 10 Dec 2023
Bispecific antibodies in NHL
Krish Patel et al. • 17 Oct 2023
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab 1:32
Assessing the dynamics of CD8-expressing cells in patients with R/R LBCL treated with glofitamab
Martin Hutchings • 11 Dec 2022
Evaluating RO7443904 in combination with glofitamab in patients with R/R NHL 1:08
Evaluating RO7443904 in combination with glofitamab in patients with R/R NHL
Martin Hutchings • 11 Dec 2022
Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL 2:43
Insights into Phase I/II study assessing fixed-duration glofitamab treatment for R/R LBCL
Martin Hutchings • 11 Dec 2022
Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL 1:46
Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL
Martin Hutchings • 11 Dec 2022
Glofitamab and polatuzumab vedotin in DLBCL 5:46
Glofitamab and polatuzumab vedotin in DLBCL
Martin Hutchings • 12 Dec 2021
NP30179: Glofitamab monotherapy in R/R NHL 0:50
NP30179: Glofitamab monotherapy in R/R NHL
Martin Hutchings • 12 Dec 2021
Preliminary results from NP40126: Glofitamab and R-CHOP in NHL 1:43
Preliminary results from NP40126: Glofitamab and R-CHOP in NHL
Martin Hutchings • 12 Dec 2021
Advances in immunotherapy for lymphoma 1:18
Advances in immunotherapy for lymphoma
Martin Hutchings • 12 Dec 2021
5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphoma 5:06
5-year follow-up of ECHELON-1: brentuximab plus AVD versus ABVD in Hodgkin lymphoma
Martin Hutchings • 9 Jun 2021
Updated efficacy data on glofitamab step-up dosing in NHL 2:18
Updated efficacy data on glofitamab step-up dosing in NHL
Martin Hutchings • 14 Jun 2021
Subcutaneous epcoritamab in R/R B-cell NHL 2:42
Subcutaneous epcoritamab in R/R B-cell NHL
Martin Hutchings • 14 Jun 2021
Bispecific antibodies for non-Hodgkin lymphoma 2:43
Bispecific antibodies for non-Hodgkin lymphoma
Martin Hutchings • 18 Jun 2020
Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma 9:41
Subcutaneous epcoritamab in R/R B-cell non-Hodgkin lymphoma
Martin Hutchings • 18 Jun 2020
The content of VJHemOnc is intended for healthcare professionals